| Chemical Properties | Back Directory | [Melting point ]
179-181 °C | [Boiling point ]
618.2±65.0 °C(Predicted) | [density ]
1.626±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
6.46±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
LLL12 is a potent STAT3 inhibitor. LLL12 inhibits colony formation and cell migration and works synergistically with doxorubicin and gemcitabine. LLL12 demonstrated a potent inhibitory activity on breast and glioblastoma tumor growth in a mouse xenograft model. LLL12 may be a potential therapeutic agent for human cancer cells expressing constitutive STAT3 signaling. | [Uses]
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1]. | [in vivo]
LLL12 (5 mg/kg; i.p.; once daily for 13 d) shows strong growth inhibition activity in mouse osteosarcoma cells and tumor growth[2]. | Animal Model: | Mouse xenografts with SJSA or OS-33 osteosarcoma cells[2] | | Dosage: | 5 mg/kg | | Administration: |
Intraperitoneal injection; once daily for 13 days
| | Result: | Resulted in a significant reduction in tumor volume and tumor mass in the OS-33 and SJSA xenografted mice.
|
| [IC 50]
p-STAT3 | [References]
[1] Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin? and paclitaxel?mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. DOI:10.3892/or.2020.7667
[2] Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. DOI:10.1007/s10637-011-9645-1 |
|
| Company Name: |
Creative Enzymes
|
| Tel: |
1-516-855-7709 |
| Website: |
www.creative-enzymes.com |
|